Docetaxel combined with cisplatin in the treatment of anthracycline-resistant advanced breast cancer.
- Author:
Bing-He XU
1
;
Long-Mei ZHAO
;
Jia-Yu WANG
;
Peng YUAN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Anthracyclines; pharmacology; therapeutic use; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Breast Neoplasms; drug therapy; pathology; Cisplatin; administration & dosage; adverse effects; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; chemically induced; Liver Neoplasms; drug therapy; secondary; Lung Neoplasms; drug therapy; secondary; Middle Aged; Nausea; chemically induced; Neutropenia; chemically induced; Remission Induction; Survival Analysis; Taxoids; administration & dosage; adverse effects; Treatment Outcome; Vomiting; chemically induced
- From: Chinese Journal of Oncology 2006;28(6):471-473
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of combination chemotherapy of Docetaxel (Taxotere, TXT) combined with cisplatin (DDP) for anthracycline (ANT)-resistant advanced breast cancer (ABC).
METHODSFrom April 2000 to March 2005, 31 patients with ANT-resistant advanced breast cancer were treated with combination chemotherapy of TXT and DDP. TXT 75 mg/m2 and DDP 75 mg/m2 were used on day 1 every three weeks. The median number of cycles was 4 (range: 2 - 8 cycles).
RESULTSThe overall combination chemotherapy response rate was 54.9% with a median time to progression of 5 months. One-year survival rate was 66.7%. The main side effects were gastrointestinal and hematologic toxicities, including grade 3 to 4 nausea and vomiting in 3 patients (9.7%), leukopenia in 6 (19.3%), and neutropenia in 3 (9.7%).
CONCLUSIONTaxotere and displatin combination is active in the treatment for anthracycine-resistant advanced breast cancer patient with an acceptable toxicity, and may be a therapeutic alternative after anthracycline regimen has failed.
